Clinical Trial Update: A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. [NA]

View source ↗

Summary

Continuation study of sunitinib malate for patients who left a prior sunitinib trial; completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Castration-resistant Prostate Cancer
• Gastric Cancer
• Gastrointestinal Stromal Tumor
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Islet Cell Carcinoma
• Pancreatic Neuroendocrine Tumor
• Renal Cell Cancer
• Thyroid Cancer

Drugs mentioned

• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Breast Cancer, Advanced Breast Cancer | NA | Status: COMPLETED | Results posted: 2015-11-06